University of Groningen VEGFC Antibody Therapy Drives Differentiation of AML

[1]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[2]  V. Guryev,et al.  Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML , 2014, Leukemia.

[3]  R. Dana,et al.  Vascular endothelial growth factor-C promotes alloimmunity by amplifying antigen-presenting cell maturation and lymphangiogenesis. , 2012, Investigative ophthalmology & visual science.

[4]  R. Dana,et al.  Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease. , 2012, Archives of ophthalmology.

[5]  S. Fröhling,et al.  AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias , 2011, Cell.

[6]  T. Haferlach,et al.  Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia , 2011, Leukemia.

[7]  W. Kamps,et al.  High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. , 2010, Blood.

[8]  E. Vellenga,et al.  Down-regulation of GATA1 uncouples STAT5-induced erythroid differentiation from stem/progenitor cell proliferation. , 2010, Blood.

[9]  Kevin R. Coombes,et al.  Highly Phosphorylated FOXO3A Is an Adverse Prognostic Factor in Acute Myeloid Leukemia , 2010, Clinical Cancer Research.

[10]  Michael Hsiao,et al.  Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. , 2009, Carcinogenesis.

[11]  J. D. Engel,et al.  GATA1-related leukaemias , 2008, Nature Reviews Cancer.

[12]  W. Kamps,et al.  Endogenous Vascular Endothelial Growth Factor-C Expression Is Associated with Decreased Drug Responsiveness in Childhood Acute Myeloid Leukemia , 2008, Clinical Cancer Research.

[13]  S. Rafii,et al.  Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. , 2002, Blood.

[14]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[15]  K. Alitalo,et al.  VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. , 2000, Blood.

[16]  K. Alitalo,et al.  Vascular endothelial growth factor C induces angiogenesis in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. Bloomfield,et al.  All-trans-retinoic acid in acute promyelocytic leukemia. , 1997, The New England journal of medicine.

[18]  S. Ergün,et al.  Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia , 1997, Leukemia.

[19]  P. Fenaux,et al.  Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group , 1993 .

[20]  Gordon B Mills,et al.  Functional proteomic profiling of AML predicts response and survival. , 2009, Blood.